Rapamycin vs Methotrexate in Diffuse SSc

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2002
This is a study to determine the safety of the immunosuppressive rapamycin in patients with systemic sclerosis with diffuse cutaneous scleroderma. The effects (both good and bad) are being compared to another group of systemic sclerosis patients receiving methotrexate
Epistemonikos ID: f4dfa9dc42206fa78afaedd8555810650f006130
First added on: May 04, 2024